Innoviva, Inc. (INVA) News
Filter INVA News Items
INVA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest INVA News From Around the Web
Below are the latest news stories about INNOVIVA INC that investors may wish to consider to help them evaluate INVA as an investment opportunity.
Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva IncIn the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on. |
Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?Most readers would already know that Innoviva's (NASDAQ:INVA) stock increased by 2.5% over the past month. However, the... |
Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 MillionDespite a decrease in net income, the company shows promise with the launch of new therapy and positive Phase 3 data |
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBURLINGAME, Calif., November 01, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives. |
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaGENEVA & WALTHAM, Mass., November 01, 2023--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in an unprecedented global pivotal Phase 3 clinical trial. Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site whe |
Calculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)Key Insights Using the 2 Stage Free Cash Flow to Equity, Innoviva fair value estimate is US$11.69 Innoviva's US$13.37... |
Innoviva to Participate in the Cantor Global Healthcare ConferenceBURLINGAME, Calif., September 19, 2023--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023 at 1:50 p.m. Eastern Time. |
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsWALTHAM, Mass., September 18, 2023--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that XACDURO® (sulbactam for injection; durlobactam for injection) is now available in the United States for patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). |
Innoviva Appoints Stephen Basso as Chief Financial OfficerBURLINGAME, Calif., August 25, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. |
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressBURLINGAME, Calif., August 02, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives. |